Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany — A retrospective cohort study
Background: The risk of thromboembolic events is increased in patients with non-valvular atrial fibrillation (NVAF) and renal impairment. The risk of bleeding events is increased if these patients are treated with anticoagulants and further increased in those with active cancer. Methods: RELOAD, a r...
Main Authors: | Hendrik Bonnemeier, Maria Huelsebeck, Sebastian Kloss |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-06-01
|
Series: | International Journal of Cardiology: Heart & Vasculature |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352906718301702 |
Similar Items
-
Rivaroxaban in non valvular atrial fibrillation: subgroups analysis
by: Cesare Greco
Published: (2015-08-01) -
Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis
by: Olivia S. Costa PharmD, et al.
Published: (2020-10-01) -
Evaluation of the anticoagulant effect of vitamin K antagonists in patients with non-valvular atrial fibrilation
by: Stanojković Zoran, et al.
Published: (2020-01-01) -
Rivaroxaban in atrial fibrillation
by: Giorgi MA, et al.
Published: (2012-08-01) -
Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation
by: Luís Silva Miguel, et al.
Published: (2016-03-01)